Aldeyra Therapeutics Files 2024 Annual Report Amendment
Ticker: ALDX · Form: 10-K/A · Filed: Mar 28, 2025 · CIK: 1341235
Sentiment: neutral
Topics: amendment, annual-report, biotech
TL;DR
Aldeyra filed its 2024 10-K amendment. Check for updates.
AI Summary
Aldeyra Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, submitted on March 28, 2025, provides updated information regarding the company's operations and financial status. Aldeyra Therapeutics is a biotechnology company focused on developing treatments for immune-mediated diseases.
Why It Matters
This amendment to the annual report provides updated disclosures for investors and stakeholders, reflecting the company's latest financial and operational status as of December 31, 2024.
Risk Assessment
Risk Level: medium — As a biotechnology company, Aldeyra Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024 — Fiscal Year End (The report covers the fiscal year ending on this date.)
- 10-K/A — Filing Type (Indicates an amendment to the annual report.)
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — Registrant
- December 31, 2024 (date) — Fiscal year end
- March 28, 2025 (date) — Filing date
- 001-36332 (company) — Commission file number
- Lexington, MA (location) — Principal executive office location
FAQ
What is the primary purpose of this 10-K/A filing?
The primary purpose is to amend the previously filed annual report for the fiscal year ended December 31, 2024, providing updated information.
When was this amendment filed with the SEC?
This amendment was filed on March 28, 2025.
What is Aldeyra Therapeutics, Inc.'s principal business address?
The principal executive office is located at 131 Hartwell Avenue, Suite 320, Lexington, MA 02421.
What is the Commission file number for Aldeyra Therapeutics, Inc.?
The Commission file number is 001-36332.
What fiscal year does this amended report cover?
This amended report covers the fiscal year ended December 31, 2024.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on March 28, 2025 regarding Aldeyra Therapeutics, Inc. (ALDX).